The earnings call reflects a predominantly positive outlook with record-high revenue, strong operating profit growth, and effective pricing strategies. However, challenges such as decreased free cash flow, temporary revenue declines in specific segments, and potential future impacts from tariffs were noted.

Company Guidance

In the earnings call for Terumo, CFO Jin Hagimoto provided a detailed overview of the financial results for the first quarter of fiscal year 2025, highlighting several key metrics. The company achieved a record-high quarterly revenue of JPY 260 billion, driven by a 6% growth in total revenue excluding foreign exchange effects, with strong demand particularly in the U.S. Operating profit reached JPY 55.9 billion, supported by improved gross margins from pricing strategies and cost control. Free cash flow was JPY 10.5 billion, a decrease of JPY 4.2 billion year-on-year, primarily due to increased inventories and tariffs. Despite negative currency impacts, the cardiovascular segment saw a 7% revenue growth in local currency, with TIS and Neuro leading the performance. The company maintained its full-year guidance, citing strong fundamentals and effective pricing measures to mitigate tariff impacts.

Record-High Quarterly Revenue

Achieved record-high quarterly revenue of JPY 260 billion for Q1, with total revenue growing by 6% excluding foreign exchange effects.

Strong Operating Profit Growth

Operating profit grew significantly faster than revenue, reaching a record JPY 55.9 billion, supported by improved gross margin from pricing strategies and cost management.

Cardiovascular Company Performance

Revenue grew 7% on a local currency basis, driven by strong performance in the U.S. TIS and Neuro led the growth, and operating margin improved by 5 points to 29%.

TBCT Blood and Cell Technologies Growth

Revenue grew significantly in plasma innovation under Global Blood Solutions, with further revenue growth expected as operations optimize.

Sustainable Price Increases

Company-wide pricing measures are having a greater-than-expected effect, especially in the Cardiovascular segment.

Terumo (JP:4543) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JP:4543 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2026 (Q2)	23.78 / -	19.75	―	―	―
Aug 07, 2025	2026 (Q1)	24.40 / 28.37	22.82	24.32% (+5.55)
May 14, 2025	2025 (Q4)	20.75 / 12.48	17.82	-29.97% (-5.34)
Feb 13, 2025	2025 (Q3)	25.63 / 23.96	20.03	19.62% (+3.93)
Nov 07, 2024	2025 (Q2)	22.12 / 19.75	18.495	6.79% (+1.25)
Aug 08, 2024	2025 (Q1)	20.89 / 22.82	15.14	50.73% (+7.68)
May 14, 2024	2024 (Q4)	18.61 / 17.82	12.875	38.41% (+4.95)
Feb 07, 2024	2024 (Q3)	19.77 / 20.03	19.94	0.45% (+0.09)
Nov 14, 2023	2024 (Q2)	15.82 / 18.50	11.88	55.68% (+6.62)
Aug 09, 2023	2024 (Q1)	17.66 / 15.14	14.805	2.26% (+0.34)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

JP:4543 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	¥2561.00	¥2530.00	-1.21%
May 14, 2025	¥2784.50	¥2726.50	-2.08%
Feb 13, 2025	¥2779.69	¥2827.47	+1.72%
Nov 07, 2024	¥2956.87	¥2965.83	+0.30%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Terumo (JP:4543) report earnings?

Terumo (JP:4543) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Terumo (JP:4543) earnings time?

Terumo (JP:4543) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Terumo stock?

The P/E ratio of Terumo is N/A.

What is JP:4543 EPS forecast?

JP:4543 EPS forecast for the fiscal quarter 2026 (Q2) is 23.78.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing